Problems and controversies in the histopathology of thyroid carcinomas of follicular cell origin

Archives of Pathology and Laboratory Medicine

Volumn 133, Issue 5, 2009, Pages 683-691

  Ghossein, Ronald ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; RADIOACTIVE IODINE;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CATALYSIS; CLINICAL FEATURE; FOLLOW UP; HISTOPATHOLOGY; PROGNOSIS; THYROID CARCINOMA; THYROID FOLLICLE CELL; THYROIDECTOMY; TUMOR VOLUME; ADENOCARCINOMA; CANCER INVASION; CELL PROLIFERATION; CLASSIFICATION; HUMAN; MITOSIS; MORTALITY; NECROSIS; REVIEW; SURVIVAL RATE; THYROID TUMOR;

ADENOCARCINOMA, FOLLICULAR; ADENOCARCINOMA, PAPILLARY; CELL PROLIFERATION; HUMANS; MITOSIS; NECROSIS; NEOPLASM INVASIVENESS; PROGNOSIS; SURVIVAL RATE; THYROID NEOPLASMS;

EID: 65649099308     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Rosai J. Poorly differentiated thyroid carcinoma: introduction to the issue, its landmarks, and clinical impact. Endocr Pathol. 2004;15:293-296.
2. Passler C, Prager G, Scheuba C, et al. Follicular variant of papillary thyroid carcinoma: a long-term follow-up. Arch Surg. 2003;138:1362-1366.
3. Carcangiu ML, Zampi G, Pupi A, Castagnoli A, Rosai J. Papillary carcinoma of the thyroid: a clinicopathologic study of 241 cases treated at the University of Florence, Italy. Cancer. 1985;55:805-828.
4. Tielens ET, Sherman SI, Hruban RH, Ladenson PW. Follicular variant of papillary thyroid carcinoma: a clinicopathologic study. Cancer. 1994;73:424-431.
5. Sebastian SO, Gonzalez JM, Paricio PP, et al. Papillary thyroid carcinoma: prognostic index for survival including the histological variety. Arch Surg. 2000;135:272-277.
6. Rosai J, Carcangiu ML, Delellis RA. Tumors of the Thyroid Gland. Washington, DC: Armed Forces Institute of Pathology; 1992. Atlas of Tumor Pathology. 3rd series; fascicle 5.
7. Chan JK. Strict criteria should be applied in the diagnosis of encapsulated follicular variantofpapillarythyroid carcinoma. AmJClinPathol. 2002;117:16-18.
8. Lloyd RV, Erickson LA, Casey MB, et al. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol. 2004;28:1336-1340.
9. Solomon BL, Wartofsky L, Burman KD. Current trends in the management of well differentiated papillary thyroid carcinoma. J Clin Endocrinol Metab. 1996;81:333-339.
10. Baloch ZW, LiVolsi VA. Encapsulated follicular variantofpapillarythyroid carcinoma with bone metastases. Mod Pathol. 2000;13:861-865.
11. Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma: an unusually high prevalence of ras mutations. Am J Clin Pathol. 2003;120:71-77.
12. Jain M, Khan A, Patwardhan N, Reale F, Safran M. Follicular variant of papillary thyroid carcinoma: a comparative study of histopathologic features and cytology results in 141 patients. Endocr Pract. 2001;7:79-84.
13. Wreesmann VB, Ghossein RA, Hezel M, et al. Follicular variant of papillary thyroid carcinoma: genome-wide appraisal of a controversial entity. GenesChro- mosomes Cancer. 2004;40:355-364.
14. Castro P, Rebocho AP, Soares RJ, et al. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. JClin Endocrinol Metab. 2006;91:213-220.
15. Liu J, Singh B, Tallini G, et al. Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity. Cancer. 2006;107:1255-1264.
16. Chem KT, Rosai J. Follicular variant of thyroid papillary carcinoma: a clin- icopathologic study of six cases. Am J Surg Pathol. 1977;1:123-130.
17. Zidan J, Karen D, Stein M, Rosenblatt E, Basher W, Kuten A. Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival. Cancer. 2003;97:1 181-1 185.
18. LiVolsi V. Pure versus follicular variantofpapillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival [comment on Cancer. 2003;97(5):1 181-1 185]. Cancer. 2003;98(9):1997.
19. Stojadinovic A, Ghossein RA, Hoos A, et al. Hurthle cell carcinoma: a critical histopathologic appraisal. J Clin Oncol. 2001;19:2616-2625.
20. Williams ED. Guest editorial: two proposals regarding the terminology of thyroid tumors. Int J Surg Pathol. 2000;8:181-183.
21. Adeniran A, Zhu Z, Gandhi M, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J SurgPathol. 2006;30:216-222.
22. Trovisco V, Vieira de Castro I, Soares P, et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. JPathol. 2004;202:247-251.
23. Nikiforova MN, Biddinger PW, Caudill CM, Kroll TG, NikiforovYE. PAX8-PPARgamma rearrangementin thyroid tumors: RT-PCR and immunohistochemicalanalyses. Am J Surg Pathol. 2002;26:1016-1023.
24. Thompson LD, Wieneke JA, Paal E, Frommelt RA, Adair CF, Heffess CS. A clinicopathologic study of minimally invasive follicular carcinoma of the thyroid gland with a review of the English literature. Cancer. 2001;91:505-524.
25. Evans HL, Vassilopoulou-Sellin R. Follicular and Hurthle cell carcinomas of the thyroid: a comparative study. Am J Surg Pathol. 1998;22:1512-1520.
26. Ghossein RA, Hiltzik DH, Carlson DL, et al. Prognostic factors of recurrence in encapsulated Hurthle cell carcinoma of the thyroid gland: a clinico- pathologic study of 50 cases. Cancer. 2006;106:1669-1676.
27. Collini P, Sampietro G, Pilotti S. Extensive vascular invasion is a marker of risk of relapse in encapsulated non-Hurthle cell follicular carcinoma of the thyroid gland: a clinicopathological study of 18 consecutive cases from a single institution with a 11-year median follow-up. Histopathology. 2004;44:35-39.
28. Lang W, Choritz H, Hundeshagen H. Risk factors in follicular thyroid car-cinomas: a retrospective follow-up study covering a 14-year period with emphasis on morphological findings. Am J Surg Pathol. 1986;10:246-255.
29. Kahn NF, Perzin KH. Follicular carcinoma of the thyroid: an evaluation of the histologic criteria used for diagnosis. Pathol Annu. 1983;(18, pt 1):221-253.
30. Hedinger C, Williams ED, Sobin LH. Histological typing ofthyroid tumors. In: International Histological Classification of Tumours. Berlin, Germany: Spring- er-Verlag; 1988. World Health Organization Classificaton of Tumours; vol 11.
31. Carcangiu ML, Zampi G, Rosai J. Poorly differentiated ("insular") thyroid carcinoma: a reinterpretation of Langhans' ''wuchernde Struma''. Am J Surg Pathol. 1984;8:655-668.
32. Sakamoto A, Kasai N, Sugano H. Poorly differentiated carcinoma of the thyroid: a clinicopathologic entity for a high-risk group of papillary and follicular carcinomas. Cancer. 1983;52:1849-1855.
33. Nishiyama RH. Another dissertation on poorly differentiated carcinomas: is it really necessary? Adv Anat Pathol. 1999;6:281-286.
34. Sakamoto A. Definition of poorly differentiated carcinoma of the thyroid: the Japanese experience. Endocr Pathol. 2004;15:307-311.
35. Sobrinho-Simoes M. Poorly differentiated thyroid carcinomas. Endocr Pathol. 1996;2:99-102.
36. Volante M, Landolfi S, Chiusa L, et al. Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns: a clinicopathologic study of 183 patients. Cancer. 2004;100:950-957.
37. Akslen LA, LiVolsi VA. Poorly differentiated thyroid carcinoma-it is important. Am J Surg Pathol. 2000;24:310-313.
38. Pilotti S, Collini P, Manzari A, Marubini E, Rilke F. Poorly differentiated forms of papillary thyroid carcinoma: distinctive entities or morphological patterns? Semin Diagn Pathol. 1995;12:249-255.
39. Nishida T, Katayama S, Tsujimoto M, Nakamura J, Matsuda H. Clinico- pathological significance of poorly differentiated thyroid carcinoma. Am J Surg Pathol. 1999;23:205-211.
40. Hiltzik D, Carlson DL, Tuttle MR, et al. Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis. Cancer. 2006;106:1286-1295.
41. Volante M, Collini P, Nikiforov YE, et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol. 2007;31:1256-1264.
42. Rivera M, Ghossein RA, Schoder H, Gomez D, Larson SM, Tuttle RM. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglu- cose-positron emission tomography-positive thyroid carcinoma. Cancer. 2008;113:48-56.
43. Wreesmann VB, Ghossein R, Patel KN, et al. Genome-wide appraisal of thyroid cancer progression. Am J Pathol. 2002;161:1549-1556.
44. Saltman B, Singh B, Hedvat C, Wreesmann VB, Ghossein R. Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression [discussion in Surgery. 2006;140:905-906]. Surgery. 2006;140:899- 905.
45. Ricarte-Filho JCM, Ryder M, Chitale DA, at al. Molecular profiling of poorly differentiated and anaplastic thyroid cancers by mass spectrometry with a thyroid cancer-specific platform reveals distinct patterns of oncogenic activation. Abstract presented at: The American Thyroid Association Meeting; October 1-5, 2008; Chicago, IL.